189 related articles for article (PubMed ID: 24349334)
1. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.
Johnson DH; Sutherland D; Acosta EP; Erdem H; Richardson D; Haas DW
PLoS One; 2013; 8(12):e82672. PubMed ID: 24349334
[TBL] [Abstract][Full Text] [Related]
2. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.
Calcagno A; Cusato J; Simiele M; Motta I; Audagnotto S; Bracchi M; D'Avolio A; Di Perri G; Bonora S
J Antimicrob Chemother; 2014 Jan; 69(1):241-5. PubMed ID: 23975735
[TBL] [Abstract][Full Text] [Related]
3. Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants.
Tsuchiya K; Hayashida T; Hamada A; Kato S; Oka S; Gatanaga H
J Acquir Immune Defic Syndr; 2014 Aug; 66(5):484-6. PubMed ID: 24872134
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 genetic polymorphisms affect opioid requirement by altering function of the intestinal P-glycoprotein.
Qin W; Zhang L; Wang X; Liu B; Xu L; Liu L; Fan B
Biomed Pharmacother; 2024 Jul; 176():116897. PubMed ID: 38850645
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants.
Tsuchiya K; Hayashida T; Hamada A; Oka S; Gatanaga H
J Acquir Immune Defic Syndr; 2016 May; 72(1):11-4. PubMed ID: 27097364
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
Yoo HD; Cho HY; Lee SN; Yoon H; Lee YB
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
[TBL] [Abstract][Full Text] [Related]
7. Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV.
Cusato J; Manca A; Palermiti A; Mula J; Avataneo V; Antonucci M; Marinaro L; Bonora S; Trunfio M; Di Perri G; D'Avolio A; Calcagno A
Int J Antimicrob Agents; 2024 Jun; 63(6):107137. PubMed ID: 38508536
[TBL] [Abstract][Full Text] [Related]
8. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
9. Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury.
Cousar JL; Conley YP; Willyerd FA; Sarnaik AA; Puccio AM; Empey PE; Kochanek PM; Bell MJ; Okonkwo DO; Clark RS
Neurocrit Care; 2013 Oct; 19(2):192-8. PubMed ID: 23896815
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
Dupuis ML; Ascione A; Palmisano L; Vella S; Cianfriglia M
BMC Pharmacol Toxicol; 2013 Sep; 14():47. PubMed ID: 24053678
[TBL] [Abstract][Full Text] [Related]
12. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
Brown KC; Hosseinipour MC; Hoskins JM; Thirumaran RK; Tien HC; Weigel R; Tauzie J; Shumba I; Lamba JK; Schuetz EG; McLeod HL; Kashuba AD; Corbett AH
Pharmacogenomics; 2012 Jan; 13(1):113-21. PubMed ID: 22111602
[TBL] [Abstract][Full Text] [Related]
13. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.
Nikisch G; Eap CB; Baumann P
Pharmacol Res; 2008; 58(5-6):344-7. PubMed ID: 18940259
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients.
Zhang ML; Chen XL; Bai ZF; Zhao X; Li WX; Wang XY; Zhang H; Chen XF; Zhang SQ; Tang JF; Xiao XH; Zhao YL
Gene; 2021 Dec; 805():145907. PubMed ID: 34411648
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
Calcagno A; D'Avolio A; Simiele M; Cusato J; Rostagno R; Libanore V; Baietto L; Siccardi M; Bonora S; Di Perri G
Br J Clin Pharmacol; 2012 Jul; 74(1):134-40. PubMed ID: 22680342
[TBL] [Abstract][Full Text] [Related]
16. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
[TBL] [Abstract][Full Text] [Related]
17. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects.
Cho HY; Yoo HD; Lee YB
Neuroscience; 2010 Aug; 169(1):378-87. PubMed ID: 20438811
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy influences the plasma pharmacokinetics but not the cerebrospinal fluid pharmacokinetics of raltegravir: a preclinical investigation.
Mahat MY; Thippeswamy BS; Khan FR; Edunuri R; Nidhyanandan S; Chaudhary S
Eur J Pharm Sci; 2014 Dec; 65():38-44. PubMed ID: 25195836
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
Yilmaz A; Gisslén M; Spudich S; Lee E; Jayewardene A; Aweeka F; Price RW
PLoS One; 2009 Sep; 4(9):e6877. PubMed ID: 19721718
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
